Fig 5.

A 51-year-old woman with a history of left lower extremity cutaneous melanoma (stage IIB) presented for routine oncologic follow-up and surveillance 3 days after receiving her first dose of the Moderna coronavirus disease 2019 vaccine in the left deltoid muscle. The primary tumor was resected 2 years prior, and she was in a clinical trial for adjuvant immunotherapy (versus placebo). Surveillance imaging studies 6 months before the current examination revealed no evidence of metastatic disease. (A,B) Axial contrast-enhanced CT images of the chest showed asymmetric mild enlargement of several left axillary and subpectoral lymph nodes (arrows) measuring up to 13 mm (short axis). The remainder of the chest CT study was otherwise unremarkable, without additional sites of lymphadenopathy or evidence of metastatic disease. After deliberation, it was recommended that the patient return to routine oncologic follow-up, with plans for routine repeat surveillance imaging in 6 months.